Analytical Characterization of USFDA Drug Lorcaserin Recently Banned – Scope for Its Existence in the Pharma Industry Analytical Characterization of Lorcaserin
Iranian Journal of Pharmaceutical Sciences,
دوره 19 شماره 1 (2023),
15 January 2023
,
صفحه 11-23
https://doi.org/10.22037/ijps.v19i1.43112
چکیده
Lorcaserin is an anti-obesity agent used to treat chronic obesity. It is a selective 5-HT receptor agonist. Lorcaserin tablet formulation is not marketed in India but was available in the US and the patent expiration happens to be in 2023, there is greater scope for the launch of generic drugs in India as well as other countries. The literature review reveals that there are several clinical data for the estimation of Lorcaserin was reported so far but there are few Analytical reports available. Therefore, the attempt at method development and validation of Lorcaserin raw material was undertaken by various analytical methodologies such as Titrimetry, UV, and HPLC methods. But Lorcaserin tablet (Belviq) was withdrawn from US Market on Feb 13, 2020, due to cancer risk. In this view, the synthetic mixtures were prepared and evaluated by the proposed HPLC Method. The developed titrimetry, UV, and HPLC methods are easy to perform and specific to Lorcaserin and pay a wider way to the characterization of newer drug substances and formulations.
- Lorcaserin
- Characterization
- Titrimetry
- UV
- HPLC
- Synthetic mixtures
ارجاع به مقاله
مراجع
. Venkatesh P, Venkat BR, Venu GK, Vinodhini S, Vinodhini T, Vinodhini C, Chitra K. A Review on Lorcaserin – A Selective 5-HT Serotonin Receptor Agonist in Obesity Management. Int J Cur Res Rev (2017) 9 (17): 37-40.
. Gustafson A, King C, Rey JA. Lorcaserin (Belviq): A Selective Serotonin 5-HT2C Agonist in the Treatment of Obesity. P T (2013) 38 (9): 525-534.
. Jason CG, Halford, Joanne AH. Lorcaserin and the role of 5-HT 2c agonist in the treatment of obesity. Clin. Med. Ther (2011) (3): 347-354.
. Chan EW, He Y, Chui CS, Wong AY, Lau WC, Wong IC. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev (2013) 14 (5): 383-392.
. Aronne L, Shanahan W, Fain R, Glicklich A, Soliman W, Li Y, Smith S. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials. Postgrad Med (2014) 126 (6): 7-18.
. Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR. APD356-004 Study Group. Lorcaserin (APD356), a selective 5-HT (2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring) (2009) 17 (3): 494-503.
. Steven. R. Smith, Neil J.Weissman, Christen M.Anderson, Matilde S. Emil Chuang, Scott Stubbe, Harold Bays, William R. Shanahan. Multicenter, Placebo-controlled Trail of Lorcaserin For Weight Management. N Engl J Med (2010) 15 (363): 245-256.
. Hurren KM, Berlie HD. Lorcaserin: an investigational serotonin 2C agonist for weight loss. Am J Health Syst Pharm (2011) 68 (21): 2029-2037.
. Kang JG, Park CY. Anti-Obesity Drugs: A Review about Their Effects and Safety. Diabetes Metab J (2012) 36 (1): 13-25.
. O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, Raether B, Anderson CM, Shanahan WR. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) (2012) 20 (7): 1426-1436.
. Chan EW, He Y, Chui CS, Wong AY, Lau WC, Wong IC. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev (2013) 14 (5): 383-392.
. Fleming JW, McClendon KS, Riche DM. New obesity agents: lorcaserin and phentermine/topiramate. Ann Pharmacother (2013) 47 (7-8): 1007-1016.
. Neil J. Weissman, Matilde Sanchez, Gary G. Koch, Steven R. Smith,William R. Shanahan, Christen M. Anderson. Echocardiographic Assessment of Cardiac Valvular Regurgitation With Lorcaserin From Analysis of 3 Phase 3 Clinical Trials. Circ Cardiovasc Imaging (2013) 9 (6): 560–567.
. Bajrai AA, Ezzeldin E, Al-Rashood KA, Raish M, Iqbal M. A Validated UPLC-MS-MS Assay for the Rapid Determination of Lorcaserin in Plasma and Brain Tissue Samples. J Anal Toxicol (2016) 40 (2): 133-139.
. Sadhana J. Rajput, Mansi A. Sathe, Swati D. Patel. Development and Validation of a HPLC-based Bioanalytical Method for Lorcaserin using Solid Phase Extraction and Application to a Pharmacokinetic Study in Rats. Indian J Pharm Sci (2018) 80 (2): 235-241.
. Chetan Kedari, Hemlata Bhavar, Sagar Magar. A review on estimation of lorcaserin hydrochloride in bulk and tablet dosage form. World J. Pharm. Res (2019) 8 (1): 677-682.
. Method for detecting content of lorcaserin hydrochloride through high performance liquid chromatography (HPLC) method. Available from: https://patents.google.com/patent/CN103901151A/en.
. Guideline ICH. Validation of analytical procedures: text and methodology Q2(R1) (2005). Available from: http://www. ich. org/cache/compo/363-272-1. html. 2017.
- چکیده مشاهده شده: 118 بار
- IJPS-43112-Galley Proof- P. 11-23 (English) دانلود شده: 70 بار